<DOC>
	<DOC>NCT01617460</DOC>
	<brief_summary>The objective of this study is to investigate the safety and efficacy of aripiprazole orally administered over long term in subjects who complete a short-term treatment study of pediatric Autistic Disorder (031-11-002 study).</brief_summary>
	<brief_title>A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>The patient meets Autistic disorder diagnostic criteria defined in DSMIVTR. The patient has completed the 03111002 study (the patient has visited the hospital during week8) Inpatient or outpatient status The patient is currently diagnosed with another disorder on the autism spectrum in DSMIVTR, including Asperger's, Rett's Disorder, PDDNOS, Childhood Disintegrative Disorder, or FragileX Syndrome. Patients who fall under a contraindication listed in the ABILIFY package insert Others</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Autistic Disorder, children and adolescents</keyword>
	<keyword>aripiprazole</keyword>
	<keyword>Long-term safety study</keyword>
	<keyword>children and adolescents</keyword>
</DOC>